Raynaud's phenomenon: From molecular pathogenesis to therapy

Autoimmunity Reviews

Volumn 13, Issue 6, 2014, Pages 655-667

  Prete, Marcella ^a   Fatone, Maria Celeste ^a   Favoino, Elvira ^a   Perosa, Federico ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

Autoantibodies; Connective tissue disease; Raynaud's phenomenon; Smooth muscle cells; Systemic sclerosis; Targeted therapy

Indexed keywords

AMBRISENTAN; ANTITHROMBOCYTIC AGENT; AUTOANTIBODY; BOSENTAN; BUFLOMEDIL; CALCITONIN GENE RELATED PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; DIHYDROPYRIDINE; ENDOTHELIN RECEPTOR; FASUDIL; FLUOXETINE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; MQX 503; NEUROKININ A; NIFEDIPINE; QUINAPRIL; SEROTONIN; SILDENAFIL; SUBSTANCE P; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ALCOHOL CONSUMPTION; AUTONOMIC NERVOUS SYSTEM; BLOOD VESSEL TONE; BLOOD VISCOSITY; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONNECTIVE TISSUE DISEASE; CYANOSIS; DEGENERATIVE DISEASE; DEGENERATIVE VASCULAR OBSTRUCTIVE DISEASES; DISEASE ASSOCIATION; DISEASE COURSE; EMOTIONAL STRESS; ERYTHEMA; FIBRINOLYSIS; FINGER ULCER; GANGRENE; HEREDITY; HUMAN; LEUKOCYTE; LIFESTYLE MODIFICATION; MACROGLOBULINEMIA; META ANALYSIS (TOPIC); MOLECULAR PATHOLOGY; MOLECULAR THERAPY; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; PALLOR; PATHOPHYSIOLOGY; PHYSICAL STRESS; POLYCYTHEMIA; POPULATION RISK; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RAYNAUD PHENOMENON; REVIEW; RISK ASSESSMENT; RISK FACTOR; SECONDARY RAYNAUD PHENOMENON; SKIN COLOR; SMOKING; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; THROMBOCYTE ACTIVATION; TREATMENT INDICATION; VASCULARIZATION; VASOCONSTRICTION; VIBRATION DISEASE;

AUTOANTIBODIES; CONNECTIVE TISSUE DISEASE; RAYNAUD'S PHENOMENON; SMOOTH MUSCLE CELLS; SYSTEMIC SCLEROSIS; TARGETED THERAPY;

ANIMALS; CONNECTIVE TISSUE DISEASES; DIAGNOSIS, DIFFERENTIAL; HUMANS; OXIDATIVE STRESS; RAYNAUD DISEASE; RISK FACTORS;

EID: 84896546898     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.12.001     Document Type: Review

References (178)

1. Noel B. Pathophysiology and classification of the vibration white finger. Int Arch Occup Environ Health 2000, 73:150-155.
2. Doll D.C., Yarbro J.W. Vascular toxicity associated with antineoplastic agents. Semin Oncol 1992, 19:580-596.
3. Garcia-Carrasco M., Jimenez-Hernandez M., Escarcega R.O., Mendoza-Pinto C., Pardo-Santos R., Levy R., et al. Treatment of Raynaud's phenomenon. Autoimmun Rev 2008, 8:62-68.
4. Herrick A.L. The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012, 8:469-479.
5. Wigley F.M. Clinical practice. Raynaud's Phenomenon. N Engl J Med 2002, 347:1001-1008.
6. Pope J.E. The diagnosis and treatment of Raynaud's phenomenon: a practical approach. Drugs 2007, 67:517-525.
7. Ingegnoli F., Boracchi P., Gualtierotti R., Lubatti C., Meani L., Zahalkova L., et al. Prognostic model based on nailfold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder: PRINCE (prognostic index for nailfold capillaroscopic examination). Arthritis Rheum 2008, 58:2174-2182.
8. Suter L.G., Murabito J.M., Felson D.T., Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005, 52:1259-1263.
9. De Angelis R., Salaffi F., Grassi W. Raynaud's phenomenon: prevalence in an Italian population sample. Clin Rheumatol 2006, 25:506-510.
10. Fraenkel L., Zhang Y., Chaisson C.E., Maricq H.R., Evans S.R., Brand F., et al. Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum 1999, 42:306-310.
11. Khanna P.P., Maranian P., Gregory J., Khanna D. The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial. Ann Rheum Dis 2010, 69:588-591.
12. Generini S., Seibold J.R., Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud's phenomenon. Rheum Dis Clin North Am 2005, 31:177. [-xi].
13. Nussinovitch U., Shoenfeld Y. The role of gender and organ specific autoimmunity. Autoimmun Rev 2012, 11:A377-A385.
14. Suter L.G., Murabito J.M., Felson D.T., Fraenkel L. Smoking, alcohol consumption, and Raynaud's phenomenon in middle age. Am J Med 2007, 120:264-271.
15. Steen V., Denton C.P., Pope J.E., Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford) 2009, 48(Suppl. 3):iii19-iii24.
16. Pistorius M.A., Planchon B., Schott J.J., Lemarec H. Heredity and genetic aspects of Raynaud's disease. J Mal Vasc 2006, 31:10-15.
17. Plaisier E., Chen Z., Gekeler F., Benhassine S., Dahan K., Marro B., et al. Novel COL4A1 mutations associated with HANAC syndrome: a role for the triple helical CB3[IV] domain. Am J Med Genet A 2010, 152A:2550-2555.
18. Herrick A.L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005, 44:587-596.
19. Sunderkotter C., Riemekasten G. Pathophysiology and clinical consequences of Raynaud's phenomenon related to systemic sclerosis. Rheumatology (Oxford) 2006, 45(Suppl. 3):iii33-iii35.
20. Edwards J.M., Taylor L.M., Porter J.M., Hobson, Wilson, Veith Raynaud's syndrome and upper extremities small artery occlusive diseases. Vascular surgery: principle and practise 2004, 903-912. Marcell Dekker, Inc, New York.
21. Katada Y., Tanaka T. Images in clinical medicine. Lingual Raynaud's phenomenon. N Engl J Med 2012, 366:e12.
22. Chikura B., Moore T., Manning J., Vail A., Herrick A.L. Thumb involvement in Raynaud's phenomenon as an indicator of underlying connective tissue disease. J Rheumatol 2010, 37:783-786.
23. Heidrich H. Functional vascular diseases: Raynaud's syndrome, acrocyanosis and erythromelalgia. Vasa 2010, 39:33-41.
24. Planchon B., Pistorius M.A., Beurrier P., De F.P. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology 1994, 45:677-686.
25. Freedman R.R., Mayes M.D. Familial aggregation of primary Raynaud's disease. Arthritis Rheum 1996, 39:1189-1191.
26. LeRoy E.C., Medsger T.A. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992, 10:485-488.
27. Kallenberg C.G. Early detection of connective tissue disease in patients with Raynaud's phenomenon. Rheum Dis Clin North Am 1990, 16:11-30.
28. Amanzi L., Braschi F., Fiori G., Galluccio F., Miniati I., Guiducci S., et al. Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology (Oxford) 2010, 49:1374-1382.
29. Chung L., Fiorentino D. Digital ulcers in patients with systemic sclerosis. Autoimmun Rev 2006, 5:125-128.
30. Guiducci S., Giacomelli R., Cerinic M.M. Vascular complications of scleroderma. Autoimmun Rev 2007, 6:520-523.
31. Meier F.M., Frommer K.W., Dinser R., Walker U.A., Czirjak L., Denton C.P., et al. Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database. Ann Rheum Dis 2012, 71:1355-1360.
32. Grader-Beck T., Wigley F.M. Raynaud's phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am 2005, 31:465-481. [vi].
33. Maldonado M.E., Perez M., Pignac-Kobinger J., Marx E.T., Tozman E.M., Greidinger E.L., et al. Clinical and immunologic manifestations of mixed connective tissue disease in a Miami population compared to a Midwestern US Caucasian population. J Rheumatol 2008, 35:429-437.
34. Nossent J., Kiss E., Rozman B., Pokorny G., Vlachoyiannopoulos P., Olesinska M., et al. Disease activity and damage accrual during the early disease course in a multinational inception cohort of patients with systemic lupus erythematosus. Lupus 2010, 19:949-956.
35. Vaz C.C., Couto M., Medeiros D., Miranda L., Costa J., Nero P., et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol 2009, 28:915-921.
36. Pope J.E., Al-Bishri J., Al-Azem H., Ouimet J.M. The temporal relationship of Raynaud's phenomenon and features of connective tissue disease in rheumatoid arthritis. J Rheumatol 2008, 35:2329-2333.
37. Garcia-Carrasco M., Siso A., Ramos-Casals M., Rosas J., de la R.G., Gil V., et al. Raynaud's phenomenon in primary Sjogren's syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol 2002, 29:726-730.
38. Pavlov-Dolijanovic S., Damjanov N.S., Stojanovic R.M., Vujasinovic Stupar N.Z., Stanisavljevic D.M. Scleroderma pattern of nailfold capillary changes as predictive value for the development of a connective tissue disease: a follow-up study of 3,029 patients with primary Raynaud's phenomenon. Rheumatol Int 2012, 32:3039-3045.
39. Koenig M., Joyal F., Fritzler M.J., Roussin A., Abrahamowicz M., Boire G., et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912.
40. Ingegnoli F., Boracchi P., Gualtierotti R., Biganzoli E.M., Zeni S., Lubatti C., et al. Improving outcome prediction of systemic sclerosis from isolated Raynaud's phenomenon: role of autoantibodies and nail-fold capillaroscopy. Rheumatology (Oxford) 2010, 49:797-805.
41. Beltran E., Toll A., Pros A., Carbonell J., Pujol R.M. Assessment of nailfold capillaroscopy by ×30 digital epiluminescence (dermoscopy) in patients with Raynaud phenomenon. Br J Dermatol 2007, 156:892-898.
42. Sunderkotter C., Herrgott I., Bruckner C., Moinzadeh P., Pfeiffer C., Gerss J., et al. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009, 160:835-843.
43. Chung L., Liu J., Parsons L., Hassoun P.M., McGoon M., Badesch D.B., et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010, 138:1383-1394.
44. Dhala A. Pulmonary arterial hypertension in systemic lupus erythematosus: current status and future direction. Clin Dev Immunol 2012, 2012:854941.
45. Shinjo S.K., Bonfa E. Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon. Clin Rheumatol 2011, 30:173-177.
46. Gronhagen C.M., Gunnarsson I., Svenungsson E., Nyberg F. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus 2010, 19:1187-1194.
47. Tang X., Huang Y., Deng W., Tang L., Weng W., Zhang X. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine (Baltimore) 2010, 89:62-67.
48. Lavras Costallat L.T., Valente Coimbra A.M. Raynaud's phenomenon in systemic lupus erythematosus. Rev Rhum Engl Ed 1995, 62:349-353.
49. Pavlov-Dolijanovic S., Damjanov N.S., Vujasinovic Stupar N.Z., Marcetic D.R., Sefik-Bukilica M.N., Petrovic R.R. Is there a difference in systemic lupus erythematosus with and without Raynaud's phenomenon?. Rheumatol Int 2013, 33:859-865.
50. Padovan M., Castellino G., Bortoluzzi A., Caniatti L., Trotta F., Govoni M. Factors and comorbidities associated with central nervous system involvement in systemic lupus erythematosus: a retrospective cross-sectional case-control study from a single center. Rheumatol Int 2012, 32:129-135.
51. Cavazzana I., Fredi M., Taraborelli M., Quinzanini M., Tincani A., Franceschini F. A subset of systemic sclerosis but not of systemic lupus erythematosus is defined by isolated anti-Ku autoantibodies. Clin Exp Rheumatol 2013, 31:118-121.
52. Furtado R.N., Pucinelli M.L., Cristo V.V., Andrade L.E., Sato E.I. Scleroderma-like nailfold capillaroscopic abnormalities are associated with anti-U1-RNP antibodies and Raynaud's phenomenon in SLE patients. Lupus 2002, 11:35-41.
53. Cefle A., Inanc M., Sayarlioglu M., Kamali S., Gul A., Ocal L., et al. Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphospholipid antibodies and severe disease outcome. Rheumatol Int 2011, 31:183-189.
54. Choojitarom K., Verasertniyom O., Totemchokchyakarn K., Nantiruj K., Sumethkul V., Janwityanujit S. Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies. Clin Rheumatol 2008, 27:345-351.
55. Xu D., Yang H., Lai C.C., Li P., Zhang X., Yang X.O., et al. Clinical analysis of systemic lupus erythematosus with gastrointestinal manifestations. Lupus 2010, 19:866-869.
56. Sayarlioglu M., Yuzbasioglu N., Inanc M., Kamali S., Cefle A., Karaman O., et al. Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int 2012, 32:177-182.
57. Liu A., Zhang W., Tian X., Zhang X., Zhang F., Zeng X. Prevalence, risk factors and outcome of digital gangrene in 2684 lupus patients. Lupus 2009, 18:1112-1118.
58. Prete M., Fatone M.C., Vacca A., Racanelli V., Perosa F. Severe pulmonary hypertension as the initial manifestation of systemic lupus erythematosus: a case report and review of the literature. Clin Exp Rheumatol Dec.16 2013, [[Epub ahead of print]. PM:24351505; http://www.ncbi.nlm.nih.gov/pubmed/24351505?dopt=Citation].
59. Ohtsuka T., Tamura T., Yamakage A., Yamazaki S. The predictive value of quantitative nailfold capillary microscopy in patients with undifferentiated connective tissue disease. Br J Dermatol 1998, 139:622-629.
60. De Angelis R., Cerioni A., Del Medico P., Blasetti P. Raynaud's phenomenon in undifferentiated connective tissue disease (UCTD). Clin Rheumatol 2005, 24:145-151.
61. Guerrero L.F., Rueda J.C., Arciniegas R., Rueda J.M. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int 2013, 33:1085-1088.
62. Calguneri M., Ureten K., Akif O.M., Onat A.M., Ertenli I., Kiraz S., et al. Extra-articular manifestations of rheumatoid arthritis: results of a university hospital of 526 patients in Turkey. Clin Exp Rheumatol 2006, 24:305-308.
63. Saraux A., Allain J., Guedes C., Baron D., Youinou P., Le G.P. Raynaud's phenomenon in rheumatoid arthritis. Br J Rheumatol 1996, 35:752-754.
64. Ramos-Casals M., Solans R., Rosas J., Camps M.T., Gil A., Del Pino-Montes J., et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore) 2008, 87:210-219.
65. Willeke P., Schluter B., Schotte H., Domschke W., Gaubitz M., Becker H. Interferon-gamma is increased in patients with primary Sjogren's syndrome and Raynaud's phenomenon. Semin Arthritis Rheum 2009, 39:197-202.
66. Launay D., Hachulla E., Hatron P.Y., Jais X., Simonneau G., Humbert M. Pulmonary arterial hypertension: a rare complication of primary Sjogren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007, 86:299-315.
67. Lim M.J., Kwon S.R., Kim S.G., Park W. A case of MCTD overlapped by Takayasu's arteritis, presenting Raynaud's phenomenon as the initial manifestation of both diseases. Rheumatol Int 2009, 29:685-688.
68. Mills J.L. Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg 2003, 16:179-189.
69. Hartmann P., Mohokum M., Schlattmann P. The association of Raynaud's syndrome with rheumatoid arthritis-a meta-analysis. Clin Rheumatol 2011, 30:1013-1019.
70. Belch J. Raynaud's phenomenon. Cardiovasc Res 1997, 33:25-30.
71. Cooke R.A. Thoracic outlet syndrome-aspects of diagnosis in the differential diagnosis of hand-arm vibration syndrome. Occup Med (Lond) 2003, 53:331-336.
72. De Roma I., Filotico R., Cea M., Procaccio P., Perosa F. Calciphylaxis in a patient with POEMS syndrome without renal failure and/or hyperparathyroidism. A case report. Ann Ital Med Int 2004, 19:283-287.
73. Racanelli V., Prete M., Minoia C., Favoino E., Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 2008, 7:352-358.
74. Hartmann P., Mohokum M., Schlattmann P. The association of Raynaud's syndrome with carpal tunnel syndrome: a meta-analysis. Rheumatol Int 2012, 32:569-574.
75. Arinsoy T., Derici U., Yuksel A., Reis K.A., Sindel S. Cyclosporine-a treatment and a rare complication: Raynaud's phenomenon. Int J Clin Pract 2005, 59:863-864.
76. Mohokum M., Hartmann P., Schlattmann P. The association of Raynaud syndrome with beta-blockers: a meta-analysis. Angiology 2012, 63:535-540.
77. McGrath S.E., Webb A., Walker-Bone K. Bleomycin-induced Raynaud's phenomenon after single-dose exposure: risk factors and treatment with intravenous iloprost infusion. J Clin Oncol 2013, 31:e51-e52.
78. Block J.A., Sequeira W. Raynaud's phenomenon. Lancet 2001, 357:2042-2048.
79. Rosenfeld M.G., Mermod J.J., Amara S.G., Swanson L.W., Sawchenko P.E., Rivier J., et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983, 304:129-135.
80. Chen L.J., Zhang F.G., Li J., Song H.X., Zhou L.B., Yao B.C., et al. Expression of calcitonin gene-related peptide in anterior and posterior horns of the spinal cord after brachial plexus injury. J Clin Neurosci 2010, 17:87-91.
81. Brain S.D., Williams T.J., Tippins J.R., Morris H.R., MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature 1985, 313:54-56.
82. Sexton P.M., Poyner D.R., Simms J., Christopoulos A., Hay D.L. Modulating receptor function through RAMPs: can they represent drug targets in themselves?. Drug Discov Today 2009, 14:413-419.
83. Bunker C.B., Goldsmith P.C., Leslie T.A., Hayes N., Foreman J.C., Dowd P.M. Calcitonin gene-related peptide, endothelin-1, the cutaneous microvasculature and Raynaud's phenomenon. Br J Dermatol 1996, 134:399-406.
84. Goldsmith P.C., Molina F.A., Bunker C.B., Terenghi G., Leslie T.A., Fowler C.J., et al. Cutaneous nerve fibre depletion in vibration white finger. J R Soc Med 1994, 87:377-381.
85. Matucci-Cerinic M., Pietrini U., Marabini S. Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis. Clin Exp Rheumatol 1990, 8:561-565.
86. Li J.L., Kaneko T., Mizuno N. Colocalization of neuronal nitric oxide synthase and neurokinin-1 receptor in striatal interneurons in the rat. Neurosci Lett 2001, 310:109-112.
87. Almeida T.A., Rojo J., Nieto P.M., Pinto F.M., Hernandez M., Martin J.D., et al. Tachykinins and tachykinin receptors: structure and activity relationships. Curr Med Chem 2004, 11:2045-2081.
88. Kummer W., Shigemoto R., Haberberger R. Smooth muscle cells are the site of neurokinin-1 receptor localization in the arterial supply of the rat sciatic nerve. Neurosci Lett 1999, 259:119-122.
89. Tuluc F., Lai J.P., Kilpatrick L.E., Evans D.L., Douglas S.D. Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 2009, 30:271-276.
90. Quartara L., Maggi C.A. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides 1997, 31:537-563.
91. Quartara L., Maggi C.A. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides 1998, 32:1-49.
92. Freedman R.R., Girgis R., Mayes M.D. Abnormal responses to endothelial agonists in Raynaud's phenomenon and scleroderma. J Rheumatol 2001, 28:119-121.
93. Smith P.J., Ferro C.J., McQueen D.S., Webb D.J. Impaired cholinergic dilator response of resistance arteries isolated from patients with Raynaud's disease. Br J Clin Pharmacol 1999, 47:507-513.
94. Couvineau A., Laburthe M. VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 2012, 166:42-50.
95. Laburthe M., Couvineau A., Tan V. Class II G protein-coupled receptors for VIP and PACAP: structure, models of activation and pharmacology. Peptides 2007, 28:1631-1639.
96. Christopoulos A., Christopoulos G., Morfis M., Udawela M., Laburthe M., Couvineau A., et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem 2003, 278:3293-3297.
97. Terenghi G., Bunker C.B., Liu Y.F., Springall D.R., Cowen T., Dowd P.M., et al. Image analysis quantification of peptide-immunoreactive nerves in the skin of patients with Raynaud's phenomenon and systemic sclerosis. J Pathol 1991, 164:245-252.
98. Bangale Y., Cavill D., Gordon T., Planque S., Taguchi H., Bhatia G., et al. Vasoactive intestinal peptide binding autoantibodies in autoimmune humans and mice. Peptides 2002, 23:2251-2257.
99. Shenoy P., Agarwal V. Phosphodiesterase inhibitors in the management of autoimmune disease. Autoimmun Rev 2010, 9:511-515.
100. Flavahan N.A., Flavahan S., Liu Q., Wu S., Tidmore W., Wiener C.M., et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000, 43:1886-1890.
101. Bailey S.R., Eid A.H., Mitra S., Flavahan S., Flavahan N.A. Rho kinase mediates cold-induced constriction of cutaneous arteries: role of alpha2C-adrenoceptor translocation. Circ Res 2004, 94:1367-1374.
102. Matucci-Cerinic M., Giacomelli R., Pignone A., Cagnoni M.L., Generini S., Casale R., et al. Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Ann Rheum Dis 2001, 60:487-494.
103. Lise M.C., Sparsa A., Marie I., Lalloue F., Ly K., Martel C., et al. Serum neurotrophin profile in systemic sclerosis. PLoS One 2010, 5:e13918.
104. Klein-Weigel P., Gutsche-Petrak B., Humpel C., Riemekasten G., Ivanov S., Heidrich H. Circulating nerve growth factor in primary and secondary Raynaud's syndrome - results of a pilot study. Vasa 2009, 38:39-45.
105. Jeremy J.Y., Mikhailidis D.P., Hutton R.A., Dandona P. The effect of cooling on in vitro vascular prostacyclin and platelet thromboxane A2 synthesis: relevance to cold-induced pathology. Microcirc Endothelium Lymphatics 1988, 4:3-20.
106. Rajagopalan S., Pfenninger D., Kehrer C., Chakrabarti A., Somers E., Pavlic R., et al. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: implications for vascular dysfunction and progression of disease. Arthritis Rheum 2003, 48:1992-2000.
107. Rychlik-Golema W., Mastej K., Adamiec R. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases. Int Angiol 2006, 25:221-227.
108. Haendler B., Hechler U., Schleuning W.D. Molecular cloning of human endothelin (ET) receptors ETA and ETB. J Cardiovasc Pharmacol 1992, 20(Suppl. 12):S1-S4.
109. Mazzuca M.Q., Khalil R.A. Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol 2012, 84:147-162.
110. Zamora M.R., O'Brien R.F., Rutherford R.B., Weil J.V. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990, 336:1144-1147.
111. Palmer K.T., Mason H. Serum endothelin concentrations in workers exposed to vibration. Occup Environ Med 1996, 53:118-124.
112. Vancheeswaran R., Azam A., Black C., Dashwood M.R. Localization of endothelin-1 and its binding sites in scleroderma skin. J Rheumatol 1994, 21:1268-1276.
113. Sulli A., Soldano S., Pizzorni C., Montagna P., Secchi M.E., Villaggio B., et al. Raynaud's phenomenon and plasma endothelin: correlations with capillaroscopic patterns in systemic sclerosis. J Rheumatol 2009, 36:1235-1239.
114. Kim H.S., Park M.K., Kim H.Y., Park S.H. Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 2010, 29:247-254.
115. Kirchengast M., Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999, 221:312-325.
116. Duprez D.A. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 2006, 24:983-991.
117. Kawaguchi Y., Takagi K., Hara M., Fukasawa C., Sugiura T., Nishimagi E., et al. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004, 50:216-226.
118. Furspan P.B., Chatterjee S., Freedman R.R. Increased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud's disease. Arthritis Rheum 2004, 50:1578-1585.
119. Lazzerini P.E., Capecchi P.L., Bisogno S., Cozzalupi M., Rossi P.C., Pasini F.L. Homocysteine and Raynaud's phenomenon: a review. Autoimmun Rev 2010, 9:181-187.
120. Buyukhatipoglu H., Buyukaslan H., Pehlivan Y., Ceylan N., Ulas T., Tarakcioglu M., et al. Increased urotensin-II activity in patients with Raynaud's phenomenon and systemic lupus erythematosus. Int J Rheum Dis 2011, 14:276-281.
121. Varga J., Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567.
122. Rajkumar V.S., Sundberg C., Abraham D.J., Rubin K., Black C.M. Activation of microvascular pericytes in autoimmune Raynaud's phenomenon and systemic sclerosis. Arthritis Rheum 1999, 42:930-941.
123. Cipriani P., Marrelli A., Benedetto P.D., Liakouli V., Carubbi F., Ruscitti P., et al. Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis 2013, 16:595-607.
124. Laplante P., Raymond M.A., Gagnon G., Vigneault N., Sasseville A.M., Langelier Y., et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: implications in the pathophysiology of systemic sclerosis. J Immunol 2005, 174:5740-5749.
125. Liakouli V., Cipriani P., Marrelli A., Alvaro S., Ruscitti P., Giacomelli R. Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 2011, 10:590-594.
126. Blaise S., Maas R., Trocme C., Kom G.D., Roustit M., Carpentier P.H., et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J Rheumatol 2009, 36:984-988.
127. Takeuchi T., Futatsuka M., Imanishi H., Yamada S. Pathological changes observed in the finger biopsy of patients with vibration-induced white finger. Scand J Work Environ Health 1986, 12:280-283.
128. de Groot P.G., Urbanus R.T., Roest M. Platelet interaction with the vessel wall. Handb Exp Pharmacol 2012, 87-110.
129. Herrick A.L., Illingworth K., Blann A., Hay C.R., Hollis S., Jayson M.I. Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Ann Rheum Dis 1996, 55:122-127.
130. Silveri F., De A.R., Poggi A., Muti S., Bonapace G., Argentati F., et al. Relative roles of endothelial cell damage and platelet activation in primary Raynaud's phenomenon (RP) and RP secondary to systemic sclerosis. Scand J Rheumatol 2001, 30:290-296.
131. Oyabu C., Morinobu A., Sugiyama D., Saegusa J., Tanaka S., Morinobu S., et al. Plasma platelet-derived microparticles in patients with connective tissue diseases. J Rheumatol 2011, 38:680-684.
132. Polidoro L., Barnabei R., Giorgini P., Petrazzi L., Ferri C., Properzi G. Platelet activation in patients with the Raynaud phenomenon. Intern Med J 2012, 42:531-535.
133. Shemirani A.H., Nagy B., Takats A.T., Zsori K.S., Andras C., Kappelmayer J., et al. Increased mean platelet volume in primary Raynaud's phenomenon. Platelets 2012, 23:312-316.
134. Marasini B., Cugno M., Bassani C., Stanzani M., Bottasso B., Agostoni A. Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon. Int J Microcirc Clin Exp 1992, 11:375-382.
135. Herrick A.L., Matucci C.M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol 2001, 19:4-8.
136. Herrick A.L., Rieley F., Schofield D., Hollis S., Braganza J.M., Jayson M.I. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994, 21:1477-1483.
137. Stoyneva Z., Lyapina M., Tzvetkov D., Vodenicharov E. Current pathophysiological views on vibration-induced Raynaud's phenomenon. Cardiovasc Res 2003, 57:615-624.
138. Bruckdorfer K.R., Hillary J.B., Bunce T., Vancheeswaran R., Black C.M. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995, 38:1060-1067.
139. Herrick A.L., Illingworth K.J., Hollis S., Gomez-Zumaquero J.M., Tinahones F.J. Antibodies against oxidized low-density lipoproteins in systemic sclerosis. Rheumatology (Oxford) 2001, 40:401-405.
140. Solans R., Motta C., Sola R., La Ville A.E., Lima J., Simeon P., et al. Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 2000, 43:894-900.
141. Greenstein D., Kester R.C. The hemorheologic effects of hand-transmitted vibration. Angiology 1997, 48:813-819.
142. Lau C.S., O'Dowd A., Belch J.J. White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. Ann Rheum Dis 1992, 51:249-252.
143. Hirschl M., Hirschl K., Lenz M., Katzenschlager R., Hutter H.P., Kundi M. Transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon identified by diagnosis of an associated disease: results of ten years of prospective surveillance. Arthritis Rheum 2006, 54:1974-1981.
144. Racanelli V., Prete M., Musaraj G., Dammacco F., Perosa F. Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 2011, 10:503-508.
145. Koenig M., Dieude M., Senecal J.L. Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies. Autoimmun Rev 2008, 7:588-593.
146. Mehra S., Walker J., Patterson K., Fritzler M.J. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013, 12:340-354.
147. Perosa F., Vicenti C., Racanelli V., Leone P., Valentini G., Dammacco F. The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3). Clin Immunol 2010, 137:60-73.
148. Favoino E., Digiglio L., Cuomo G., Favia I.E., Racanelli V., Valentini G., et al. Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis. PLoS One 2013, 8:e61453.
149. Fineschi S., Cozzi F., Burger D., Dayer J.M., Meroni P.L., Chizzolini C. Anti-fibroblast antibodies detected by cell-based ELISA in systemic sclerosis enhance the collagenolytic activity and matrix metalloproteinase-1 production in dermal fibroblasts. Rheumatology (Oxford) 2007, 46:1779-1785.
150. Sgonc R., Gruschwitz M.S., Boeck G., Sepp N., Gruber J., Wick G. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis Rheum 2000, 43:2550-2562.
151. Flavahan N.A., Flavahan S., Mitra S., Chotani M.A. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003, 29:275-291. [vi].
152. Kowal-Bielecka O., Landewe R., Avouac J., Chwiesko S., Miniati I., Czirjak L., et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009, 68:620-628.
153. Csiki Z., Garai I., Shemirani A.H., Papp G., Zsori K.S., Andras C., et al. The effect of metoprolol alone and combined metoprolol-felodipin on the digital microcirculation of patients with primary Raynaud's syndrome. Microvasc Res 2011, 82:84-87.
154. Coleiro B., Marshall S.E., Denton C.P., Howell K., Blann A., Welsh K.I., et al. Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) 2001, 40:1038-1043.
155. Anderson M.E., Moore T.L., Hollis S., Jayson M.I., King T.A., Herrick A.L. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud's phenomenon and systemic sclerosis. Rheumatology (Oxford) 2002, 41:324-328.
156. Chung L., Shapiro L., Fiorentino D., Baron M., Shanahan J., Sule S., et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial. Arthritis Rheum 2009, 60:870-877.
157. Hummers L.K., Dugowson C.E., Dechow F.J., Wise R.A., Gregory J., Michalek J., et al. A multi-centre, blinded, randomised, placebo-controlled, laboratory-based study of MQX-503, a novel topical gel formulation of nitroglycerine, in patients with Raynaud phenomenon. Ann Rheum Dis 2013, 72:1962-1967.
158. Gliddon A.E., Dore C.J., Black C.M., McHugh N., Moots R., Denton C.P., et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud's phenomenon: a multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum 2007, 56:3837-3846.
159. Rajagopalan S., Pfenninger D., Somers E., Kehrer C., Chakrabarti A., Mukherjee D., et al. Effects of cilostazol in patients with Raynaud's syndrome. Am J Cardiol 2003, 92:1310-1315.
160. Caglayan E., Axmann S., Hellmich M., Moinzadeh P., Rosenkranz S. Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 2012, 172:1182-1184.
161. Denton C.P., Howell K., Stratton R.J., Black C.M. Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clin Exp Rheumatol 2000, 18:499-502.
162. Thompson A.E., Pope J.E. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005, 44:145-150.
163. Vinjar B., Stewart M. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2008, CD006687.
164. Schiopu E., Hsu V.M., Impens A.J., Rothman J.A., McCloskey D.A., Wilson J.E., et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 2009, 36:2264-2268.
165. Herrick A.L., van den H.F., Gabrielli A., Tamimi N., Reid C., O'Connell D., et al. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum 2011, 63:775-782.
166. Thompson A.E., Shea B., Welch V., Fenlon D., Pope J.E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001, 44:1841-1847.
167. Pope J., Fenlon D., Thompson A., Shea B., Furst D., Wells G., et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 2000, CD000953.
168. Kawald A., Burmester G.R., Huscher D., Sunderkotter C., Riemekasten G. Low versus high-dose iloprost therapy over 21days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study. J Rheumatol 2008, 35:1830-1837.
169. Milio G., Corrado E., Genova C., Amato C., Raimondi F., Almasio P.L., et al. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatology (Oxford) 2006, 45:999-1004.
170. Scorza R., Caronni M., Mascagni B., Berruti V., Bazzi S., Micallef E., et al. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study. Clin Exp Rheumatol 2001, 19:503-508.
171. Korn J.H., Mayes M., Matucci C.M., Rainisio M., Pope J., Hachulla E., et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004, 50:3985-3993.
172. Matucci-Cerinic M., Denton C.P., Furst D.E., Mayes M.D., Hsu V.M., Carpentier P., et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2011, 70:32-38.
173. Rosato E., Molinaro I., Borghese F., Rossi C., Pisarri S., Salsano F. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension. J Rheumatol 2010, 37:2531-2539.
174. Shenoy P.D., Kumar S., Jha L.K., Choudhary S.K., Singh U., Misra R., et al. Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial. Rheumatology (Oxford) 2010, 49:2420-2428.
175. Fava A., Wung P.K., Wigley F.M., Hummers L.K., Daya N.R., Ghazarian S.R., et al. Efficacy of Rho kinase inhibitor fasudil in secondary Raynaud's phenomenon. Arthritis Care Res (Hoboken) 2012, 64:925-929.
176. Abou-Raya A., Abou-Raya S., Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers. J Rheumatol 2008, 35:1801-1808.
177. Rosato E., Borghese F., Pisarri S., Salsano F. The treatment with N-acetylcysteine of Raynaud's phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol 2009, 28:1379-1384.
178. Parisi S., Peroni C.L., Lagana A., Scarati M., Ambrogio F., Bruzzone M., et al. Efficacy of ambrisentan in the treatment of digital ulcers in patients with systemic sclerosis: a preliminary study. Rheumatology (Oxford) 2013, 52:1142-1144.